FY2024 Earnings Estimate for TARS Issued By Lifesci Capital

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Equities research analysts at Lifesci Capital lifted their FY2024 EPS estimates for shares of Tarsus Pharmaceuticals in a report issued on Thursday, November 14th. Lifesci Capital analyst C. Jubinville now forecasts that the company will post earnings per share of ($3.05) for the year, up from their prior forecast of ($3.89). The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.41) per share. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals’ Q4 2024 earnings at ($0.55) EPS.

A number of other research analysts also recently commented on TARS. Oppenheimer lifted their price objective on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. William Blair upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Finally, The Goldman Sachs Group raised their target price on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research note on Friday. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $54.20.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS opened at $44.63 on Monday. The firm has a 50-day moving average of $38.11 and a 200-day moving average of $32.60. Tarsus Pharmaceuticals has a one year low of $15.60 and a one year high of $52.99. The company has a market cap of $1.71 billion, a PE ratio of -11.71 and a beta of 1.00. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 6.99.

Institutional Trading of Tarsus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of TARS. Quest Partners LLC acquired a new stake in Tarsus Pharmaceuticals in the 2nd quarter worth about $61,000. Canada Pension Plan Investment Board acquired a new stake in Tarsus Pharmaceuticals in the 2nd quarter worth about $114,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Tarsus Pharmaceuticals by 33.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock worth $166,000 after purchasing an additional 1,530 shares in the last quarter. FMR LLC raised its stake in Tarsus Pharmaceuticals by 236.6% in the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after purchasing an additional 3,537 shares in the last quarter. Finally, Dark Forest Capital Management LP acquired a new stake in Tarsus Pharmaceuticals in the 2nd quarter worth about $202,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.